{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:13:56Z","timestamp":1791465236891,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clbc.2024.11.019","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:41:36Z","timestamp":1733848896000},"page":"251-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-9269","authenticated-orcid":false,"given":"Sailaja","family":"Kamaraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Tarima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna N.","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Burkard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Giever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee C.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Parkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Pipp-Dahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hegeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nauman","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Rajguru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyleigh","family":"Twaroski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Zurbriggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Jorns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallgeir","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinton J.","family":"Keigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott B.","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Sahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Wisinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2024.11.019_bib0001","unstructured":"Breast cancer- metastatic: statistics, https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/metastatic-breast-cancer.html, 2023."},{"issue":"12","key":"10.1016\/j.clbc.2024.11.019_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.48069","article-title":"Estimated prevalence of metastatic breast cancer in England, 2016-2021","volume":"5","author":"Palmieri","year":"2022","journal-title":"JAMA Network Open"},{"issue":"25","key":"10.1016\/j.clbc.2024.11.019_bib0003","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2024.11.019_bib0004","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"New Eng J Med"},{"issue":"32","key":"10.1016\/j.clbc.2024.11.019_bib0005","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.clbc.2024.11.019_bib0006","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2024.11.019_bib0007","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2024.11.019_bib0008","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1210\/me.2015-1152","article-title":"Progesterone regulation of proliferation in the normal human breast and in breast cancer: a tale of two scenarios?","volume":"29","author":"Hilton","year":"2015","journal-title":"Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.clbc.2024.11.019_bib0009","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nrc.2016.116","article-title":"Deciphering the divergent roles of progestogens in breast cancer","volume":"17","author":"Carroll","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"1-2","key":"10.1016\/j.clbc.2024.11.019_bib0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10911-015-9339-y","article-title":"Impact of progesterone on stem\/progenitor cells in the human breast","volume":"20","author":"Hilton","year":"2015","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"2","key":"10.1016\/j.clbc.2024.11.019_bib0011","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrc3518-c1","article-title":"Is progesterone a neutral or protective factor for breast cancer?","volume":"14","author":"Muti","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"7560","key":"10.1016\/j.clbc.2024.11.019_bib0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ER\u03b1 action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.clbc.2024.11.019_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/endocr\/bqab060","article-title":"Leveraging antiprogestins in the treatment of metastatic breast cancer","volume":"162","author":"Kamaraju","year":"2021","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.clbc.2024.11.019_bib0014","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0003-9861(92)90083-9","article-title":"ZK98299\u2013a new antiprogesterone: biochemical characterization of steroid binding parameters in the calf uterine cytosol","volume":"292","author":"Nath","year":"1992","journal-title":"Arch Biochem Biophys"},{"issue":"10-11","key":"10.1016\/j.clbc.2024.11.019_bib0015","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0039-128X(00)00178-1","article-title":"Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity","volume":"65","author":"Elger","year":"2000","journal-title":"Steroids"},{"issue":"1 Suppl 1","key":"10.1016\/j.clbc.2024.11.019_bib0016","first-page":"43","article-title":"Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients","volume":"12","author":"Morgan","year":"1985","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2024.11.019_bib0017","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<730::AID-CNCR10>3.0.CO;2-0","article-title":"A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group","volume":"79","author":"Buzdar","year":"1997","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clbc.2024.11.019_bib0018","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1093\/annonc\/mdt216","article-title":"Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer","volume":"24","author":"Jonat","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.11.019_bib0019","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1186\/s40064-016-2457-1","article-title":"A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer","volume":"5","author":"Nanda","year":"2016","journal-title":"Springerplus"},{"issue":"2","key":"10.1016\/j.clbc.2024.11.019_bib0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006098910000","article-title":"Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice","volume":"49","author":"El Etreby","year":"1998","journal-title":"Breast Cancer Res Treat"},{"issue":"3-5","key":"10.1016\/j.clbc.2024.11.019_bib0021","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jsbmb.2009.05.013","article-title":"Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone","volume":"116","author":"Nishino","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.clbc.2024.11.019_bib0022","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/BF01236387","article-title":"Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384","volume":"120","author":"Nishino","year":"1994","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2024.11.019_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204973","article-title":"Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers","volume":"13","author":"Cottu","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clbc.2024.11.019_bib0024","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2967\/jnumed.111.098319","article-title":"Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16\u03b1,17\u03b1-[(R)-(1\u2032-\u03b1-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione","volume":"53","author":"Dehdashti","year":"2012","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.clbc.2024.11.019_bib0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41467-020-20814-9","article-title":"Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy","volume":"12","author":"Dehdashti","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.clbc.2024.11.019_bib0026","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cpet.2023.04.008","article-title":"Estrogen receptor-targeted and progesterone receptor-targeted PET for patients with breast cancer","volume":"18","author":"Ulaner","year":"2023","journal-title":"PET Clin"},{"issue":"2","key":"10.1016\/j.clbc.2024.11.019_bib0027","first-page":"119","article-title":"Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer","volume":"8","author":"Salem","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"25","key":"10.1016\/j.clbc.2024.11.019_bib0028","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2024.11.019_bib0029","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/1078-0432.CCR-22-2060","article-title":"Beneficial effects of mifepristone treatment in patients with breast cancer selected by the progesterone receptor isoform ratio: results from the MIPRA trial","volume":"29","author":"El\u00eda","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clbc.2024.11.019_bib0030","first-page":"e28318","article-title":"Clinical utility of mifepristone: apprising the expanding horizons","volume":"14","author":"Karena","year":"2022","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.clbc.2024.11.019_bib0031","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1078-0432.CCR-21-4049","article-title":"Phase I\/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer","volume":"28","author":"Serritella","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2024.11.019_bib0032","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13073-022-01063-5","article-title":"Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women","volume":"14","author":"Bartlett","year":"2022","journal-title":"Genome Med"},{"issue":"10","key":"10.1016\/j.clbc.2024.11.019_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140795","article-title":"Ulipristal acetate inhibits progesterone receptor isoform a-mediated human breast cancer proliferation and BCl2-L1 expression","volume":"10","author":"Esber","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clbc.2024.11.019_bib0034","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-021-06503-1","article-title":"The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation","volume":"192","author":"Westhoff","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clbc.2024.11.019_bib0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/1078-0432.CCR-19-0443","article-title":"Selective progesterone receptor modulators in early-stage breast cancer: a randomized, placebo-controlled phase II window-of-opportunity trial using telapristone acetate","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.clbc.2024.11.019_bib0036","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-10-3321","article-title":"Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer","volume":"17","author":"Linden","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1-2","key":"10.1016\/j.clbc.2024.11.019_bib0037","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1006982528297","article-title":"Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells","volume":"199","author":"Hurd","year":"1999","journal-title":"Mol Cell Biochem"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T09:56:46Z","timestamp":1741946206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924003331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1526820924003331"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.11.019","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}